Novartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma |
| April 22, 2020 | April 2020 Bond Updates |
|
EAST HANOVER, N.J., April 22, 2020 /PRNewswire/ -- Novartis today announced that the US Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to Kymriah® (tisagenlecleucel), for an investigational new indication to treat patients with... |
| View more at: https://www.prnewswire.com:443/news-releases/novartis-kymriah-receives-fda-regenerative-medicine-advanced-therapy-designation-in-follicular-lymphoma-301044971.html |
| Related News |